Phosphodiesterases: genes and their variants, inhibitors and potential therapeutic applications

References

• Halpin DM. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis.3(4), 543–561 (2008).
   PubMedGoogle Scholar
• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem.76, 481–511 (2007).
   PubMed Web of Science ®Google Scholar
• Nikolaev VO, Gambaryan S, Engelhardt S, Walter U, Lohse MJ. Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis. J. Biol. Chem.280(3), 1716–1719 (2005).
   PubMed Web of Science ®Google Scholar
• Fatemi SH, King DP, Reutiman TJ et al. PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr. Res.101(1–3), 36–49 (2008).
   PubMed Web of Science ®Google Scholar
• Huang SH, Pittler SJ, Huang X, Oliveira L, Berson EL, Dryja TP. Autosomal recessive retinitis pigmentosa caused by mutations in the α subunit of rod cGMP phosphodiesterase. Nat. Genet.11(4), 468–471 (1995).
   PubMed Web of Science ®Google Scholar
• Luo HR, Wu GS, Dong C et al. Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatr. Dis. Treat.5, 163–170 (2009).
   PubMed Web of Science ®Google Scholar
• Horvath A, Boikos S, Giatzakis C et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Genet.38(7), 794–800 (2006).
   PubMed Web of Science ®Google Scholar
• Horvath A, Giatzakis C, Robinson-White A et al. Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res.66(24), 11571–11575 (2006).
   PubMed Web of Science ®Google Scholar
• Horvath A, Korde L, Greene MH et al. Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res.69(13), 5301–5306 (2009).
   PubMed Web of Science ®Google Scholar
• Faucz FR, Horvath A, Rothenbuhler A et al. Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. J. Clin. Endocrinol. Metab.96(1), E135–E140 (2011).
   Google Scholar
• Schmidt CJ, Chapin DS, Cianfrogna J et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther.325(2), 681–690 (2008).
   PubMed Web of Science ®Google Scholar
• Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J. Pharmacol. Exp. Ther.328(3), 785–795 (2009).
   PubMed Web of Science ®Google Scholar
• Verhoest PR, Chapin DS, Corman M et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J. Med. Chem.52(16), 5188–5196 (2009).
   PubMed Web of Science ®Google Scholar
• D’andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S. Expression of PDE11A in normal and malignant human tissues. J. Histochem. Cytochem.53(7), 895–903 (2005).
   PubMed Web of Science ®Google Scholar
• Luedders DW, Muenz BM, Li F et al. Role of cGMP in sildenafil-induced activation of endothelial Ca2+-activated K+ channels. J. Cardiovasc. Pharmacol.47(3), 365–370 (2006).
   PubMed Web of Science ®Google Scholar
• Hotston M, Shukla N, Bloor J, Persad R, Jeremy JY. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int.98(6), 1331–1332 (2006).
   PubMed Web of Science ®Google Scholar
• Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr. Opin. Urol.20(1), 49–54 (2010).
   PubMed Web of Science ®Google Scholar
• Wong P, Lawrentschuk N, Bolton DM. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Curr. Opin. Urol.19(1), 7–12 (2009).
   PubMed Web of Science ®Google Scholar
• Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J. Cell. Biochem.94(2), 336–350 (2005).
   PubMed Web of Science ®Google Scholar
• Tinsley HN, Gary BD, Keeton AB et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol. Cancer Ther.8(12), 3331–3340 (2009).
   PubMed Web of Science ®Google Scholar
• Cook AL, Haynes JM. Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal16(2), 253–261 (2004).
   PubMed Web of Science ®Google Scholar
• Hood J, Granger HJ. Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J. Biol. Chem.273(36), 23504–23508 (1998).
   PubMed Web of Science ®Google Scholar
• Pyriochou A, Zhou Z, Koika V et al. The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J. Cell Physiol.211(1), 197–204 (2007).
   PubMed Web of Science ®Google Scholar
• Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu. Rev. Physiol.57, 707–736 (1995).
   PubMed Web of Science ®Google Scholar
• Zhao Z, Francis CE, Welch G, Loscalzo J, Ravid K. Reduced glutathione prevents nitric oxide-induced apoptosis in vascular smooth muscle cells. Biochim. Biophys. Acta1359(2), 143–152 (1997).
   PubMed Web of Science ®Google Scholar
• Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am. J. Physiol.267(5 Pt 1), C1405–C1413 (1994).
   PubMed Web of Science ®Google Scholar
• Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol.65, 1–52 (2001).
   PubMed Web of Science ®Google Scholar
• Weeks JL 2nd, Zoraghi R, Francis SH, Corbin JD. N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry46(36), 10353–10364 (2007).
   PubMed Web of Science ®Google Scholar
• Porst H, Hell-Momeni K, Buttner H. [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. Urologe A48(11), 1318, 1320–1319 (2009).
   PubMedGoogle Scholar
• Desiniotis A, Schafer G, Klocker H, Eder IE. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Int. J. Cancer126(3), 775–789 (2010).
   PubMed Web of Science ®Google Scholar
• Merkle D, Hoffmann R. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal23(3), 507–515 (2011).
   PubMed Web of Science ®Google Scholar
• Maioli E, Torricelli C, Fortino V. Functional interactions of protein kinase A and C in signalling networks: a recapitulation. Cell Mol. Life Sci.63(6), 637–641 (2006).
   PubMed Web of Science ®Google Scholar
• Yadav V, Denning MF. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol. Carcinog.50(5), 346–352 (2011).
   PubMed Web of Science ®Google Scholar